Peer-influenced content. Sources you trust. No registration required. This is HCN.

BloodDaratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial

In conclusion, daratumumab (Darzalex) (D) was added to lenalidomide, bortezomib, and dexamethasone (RVd) in NDMM patients who were transplant-eligible, and this led to enhanced stringent complete response (sCR) and minimal residual disease (MRD)-negative rates, a tolerable safety profile, and no clinically meaningful effects on stem cell mobilization or engraftment. These findings suggest that the D-RVd combination may become a new standard of care for NDMM who are transplant-eligible.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form